Erste Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $491K | Hold |
4,300
| – | – | ﹤0.01% | 633 |
|
|
2025
Q1 | $463K | Hold |
4,300
| – | – | 0.01% | 436 |
|
|
2024
Q4 | $470K | Hold |
4,300
| – | – | 0.01% | 442 |
|
|
2024
Q3 | $419K | Hold |
4,300
| – | – | 0.01% | 454 |
|
|
2024
Q2 | $354K | Hold |
4,300
| – | – | ﹤0.01% | 445 |
|
|
2024
Q1 | $306K | Hold |
4,300
| – | – | ﹤0.01% | 458 |
|
|
2023
Q4 | $309K | Hold |
4,300
| – | – | ﹤0.01% | 458 |
|
|
2023
Q3 | $264K | Hold |
4,300
| – | – | ﹤0.01% | 463 |
|
|
2023
Q2 | $312K | Hold |
4,300
| – | – | 0.01% | 460 |
|
|
2023
Q1 | $307K | Hold |
4,300
| – | – | 0.01% | 470 |
|
|
2022
Q4 | $291K | Sell |
4,300
-2,593
| -38% | -$175K | 0.01% | 461 |
|
|
2022
Q3 | $368K | Hold |
6,893
| – | – | 0.01% | 451 |
|
|
2022
Q2 | $380K | Hold |
6,893
| – | – | 0.01% | 456 |
|
|
2022
Q1 | $500K | Hold |
6,893
| – | – | 0.01% | 436 |
|
|
2021
Q4 | $700K | Hold |
6,893
| – | – | 0.01% | 392 |
|
|
2021
Q3 | $602K | Hold |
6,893
| – | – | 0.01% | 385 |
|
|
2021
Q2 | $581K | Hold |
6,893
| – | – | 0.01% | 391 |
|
|
2021
Q1 | $641K | Hold |
6,893
| – | – | 0.02% | 369 |
|
|
2020
Q4 | $425K | Sell |
6,893
-4,649
| -40% | -$287K | 0.01% | 401 |
|
|
2020
Q3 | $690K | Hold |
11,542
| – | – | 0.02% | 329 |
|
|
2020
Q2 | $814K | Hold |
11,542
| – | – | 0.03% | 303 |
|
|
2020
Q1 | $513K | Hold |
11,542
| – | – | 0.03% | 305 |
|
|
2019
Q4 | $769K | Hold |
11,542
| – | – | 0.03% | 299 |
|
|
2019
Q3 | $712K | Hold |
11,542
| – | – | 0.04% | 295 |
|
|
2019
Q2 | $821K | Hold |
11,542
| – | – | 0.04% | 263 |
|
|
2019
Q1 | $889K | Hold |
11,542
| – | – | 0.05% | 258 |
|
|
2018
Q4 | $986K | Buy |
+11,542
| New | +$986K | 0.07% | 237 |
|